The World Health Organization (WHO) today announced the addition of noma (cancrum oris or gangrenous stomatitis) in its official list of neglected tropical diseases (NTDs), a critical step toward tackling one of the world’s most underrecognized health concerns. The 17th meeting of the Strategic and Technical Advisory Group for Neglected Tropical Diseases (STAG-NTD) approved this decision, which shows WHO’s commitment to expanding health care to the world’s most vulnerable populations.
Noma, a severe gangrenous disease of the lips and face, typically affects malnourished young children (aged 2 to 6 years) in impoverished areas. It begins as gum irritation and develops swiftly to destroy facial tissues and bones if not treated early. It frequently results in death, leaving survivors with serious disfigurement.
Accurate assessment of the number of noma cases is difficult due to the disease’s rapid progression and associated stigma, which contributes to many instances going misdiagnosed. Noma is predominantly common in Sub-Saharan Africa, but it has also been reported in the Americas and Asia.
Noma appears to be caused by bacteria present in the mouth, according to evidence. This condition is connected with several risk factors, including poor dental hygiene, malnutrition, impaired immune systems, infections, and extreme poverty. Noma is not communicable, although it prefers to attack when the body’s defenses are weak.
Early identification is critical since medication is most successful when the disease causes severe swollen gums, a condition known as acute necrotizing gingivitis. Antibiotics are utilized in treatment, as well as advice and support on how to enhance oral hygiene with disinfectant mouthwash (salt water or chlorhexidine can be used) and nutritional supplements. If the condition is detected early on, treatment can result in good wound healing with no long-term complications. Surgery, on the other hand, may be required in extreme situations. Children who survive the gangrenous stage of the disease are at risk of severe facial deformities, difficulties eating and speaking, social shame and isolation, and reconstructive surgery.
“Noma is more than a disease, it is a social marker of extreme poverty and malnutrition, affecting the most vulnerable populations,” said Dr Tedros Adhanom Ghebreyesus, WHO Director-General. “By classifying noma as a neglected tropical disease, we are shining a light on a condition that has afflicted marginalized communities for centuries. We are committed to working with affected countries and communities to address the drivers of noma, and alleviate the suffering it causes.”
The designation of noma as a non-communicable disease (NTD) intends to raise worldwide awareness, catalyze research, stimulate funding, and boost efforts to control the condition through multisectoral and multi-pronged approaches. Interventions addressing the burden of this deadly disease will help achieve universal health care by explicitly targeting pockets of underserved communities.
Noma is frequently managed by oral health programs in endemic areas, and operational coordination with NTD programs can be increased, particularly by incorporating noma into efforts targeted at detecting and managing skin-related neglected tropical illnesses (skin NTDs).
The Nigerian government initiated the effort to include noma in the list of NTDs. An official request was made to WHO on behalf of 32 Member States in January 2023. The request was accompanied by a detailed dossier showing the burden and distribution of noma and presenting information to verify compliance with WHO’s requirements. Several partner institutions helped by providing information and advocating.
The formal process for adding new conditions to the NTD list was established by the STAG-NTD in 2016. Since then, the following diseases have been added: mycetoma (2016); chromoblastomycosis and other deep mycoses (2017; merged in a single group with mycetoma); scabies (2017); snakebite envenoming (2017); and noma (2023). Currently, with noma, WHO’s NTD list includes 21 diseases or groups of diseases.
Source: World Health Organization
more recommended stories
-
Fentanyl Inhalation: Brain Damage Risks
After treating a middle-aged man who.
-
Neurocardiac Connectivity in Depression Treatment
Heart rate deceleration and sadness may.
-
Brain Age Estimation: EEG Advancements in Neurology
To estimate brain age using EEG.
-
Neurodegeneration Linked to Fibrin in Brain Injury
The health results for the approximately.
-
DELiVR: Advancing Brain Cell Mapping with AI and VR
DELiVR is a novel AI-based method.
-
Retinal Neurodegeneration in Parkinson’s Disease
By measuring the thickness of the.
-
Epilepsy Seizures: Role of Astrocytes in Neural Hyperactivity
Roughly 1% of people experience epilepsy.
-
Epilepsy Surgery: Rare Hemorrhagic Complications Study
Following cranial Epilepsy Surgery, hemorrhagic complications.
-
Brain Connectivity Unveils New Insights into Autism
Because autism spectrum disease symptoms can.
-
Nutrient Optimization: Vitamin D for Health
Researchers addressed the prevalence of vitamin.
Leave a Comment